Gilead Sciences, Inc. (GILD) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $132.04 (+0.93%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 8, 2026 | Gregory Renza | Truist Financial | $155.00 | +17.4% |
| Mar 10, 2026 | Akash Tewari | Jefferies | $180.00 | +36.3% |
| Feb 11, 2026 | Louise Chen | Scotiabank | $177.00 | +34.1% |
| Feb 11, 2026 | Courtney Breen | Bernstein | $160.00 | +21.2% |
| Feb 11, 2026 | Joseph Stringer | Needham | $170.00 | +28.7% |
| Feb 11, 2026 | Evan Seigerman | BMO Capital | $160.00 | +21.2% |
| Feb 11, 2026 | Mohit Bansal | Wells Fargo | $165.00 | +25.0% |
| Jan 26, 2026 | Evan David Seigerman | BMO Capital | $150.00 | +13.6% |
| Jan 7, 2026 | Michael Yee | UBS | $145.00 | +9.8% |
| Dec 29, 2025 | Courtney Breen | Bernstein | $135.00 | +2.2% |
| Dec 15, 2025 | Alexandria Hammond | Wolfe Research | $150.00 | +13.6% |
| Nov 25, 2025 | Evan David Seigerman | BMO Capital | $135.00 | +2.2% |
| Nov 24, 2025 | Gregory Renza | Truist Financial | $140.00 | +6.0% |
| Oct 31, 2025 | Terence Flynn | Morgan Stanley | $147.00 | +11.3% |
| Oct 9, 2025 | Carter Gould | Cantor Fitzgerald | $135.00 | +2.2% |
| Aug 11, 2025 | James Shin | Deutsche Bank | $135.00 | +2.2% |
| Aug 8, 2025 | Brian Skorney | Robert W. Baird | $108.00 | -18.2% |
| Aug 8, 2025 | Terence Flynn | Morgan Stanley | $143.00 | +8.3% |
| Jul 14, 2025 | David Risinger | Leerink Partners | $114.00 | -13.7% |
| Jun 18, 2025 | Terence Flynn | Morgan Stanley | $135.00 | +2.2% |
Top Analysts Covering GILD
GILD vs Sector & Market
| Metric | GILD | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.06 | 2.24 | 2.41 |
| Analyst Count | 18 | 8 | 18 |
| Target Upside | +22.6% | +1150.2% | +14.9% |
| P/E Ratio | 19.50 | 6.85 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $29.82B | $30.23B | $30.80B | 20 |
| 2027-03-31 | $7.06B | $7.26B | $7.67B | 5 |
| 2027-06-30 | $7.49B | $7.71B | $8.14B | 6 |
| 2027-09-30 | $7.81B | $8.03B | $8.49B | 9 |
| 2027-12-31 | $8.50B | $8.75B | $9.24B | 5 |
| 2028-03-31 | $7.64B | $7.87B | $8.31B | 4 |
| 2028-06-30 | $8.00B | $8.23B | $8.70B | 6 |
| 2028-09-30 | $8.32B | $8.56B | $9.04B | 9 |
| 2028-12-31 | $8.61B | $8.86B | $9.36B | 4 |
| 2029-12-31 | $35.28B | $36.24B | $37.51B | 11 |
| 2030-12-31 | $36.97B | $37.98B | $39.31B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $8.21 | $8.55 | $8.82 | 17 |
| 2027-03-31 | $2.10 | $2.18 | $2.34 | 5 |
| 2027-06-30 | $2.27 | $2.36 | $2.54 | 5 |
| 2027-09-30 | $2.45 | $2.54 | $2.73 | 5 |
| 2027-12-31 | $2.63 | $2.73 | $2.93 | 5 |
| 2028-03-31 | $0.00 | $0.00 | $0.00 | 6 |
| 2028-06-30 | $0.00 | $0.00 | $0.00 | 6 |
| 2028-09-30 | $0.00 | $0.00 | $0.00 | 7 |
| 2028-12-31 | $0.00 | $0.00 | $0.00 | 9 |
| 2029-12-31 | $11.41 | $11.81 | $12.35 | 3 |
| 2030-12-31 | $12.32 | $12.76 | $13.34 | 3 |
Frequently Asked Questions
What is the analyst consensus for GILD?
The consensus among 18 analysts covering Gilead Sciences, Inc. (GILD) is Buy with an average price target of $158.71.
What is the highest price target for GILD?
The highest price target for GILD is $180.00, set by Akash Tewari at Jefferies on 2026-03-10.
What is the lowest price target for GILD?
The lowest price target for GILD is $54.00, set by Colin Bristow at UBS on 2022-02-24.
How many analysts cover GILD?
18 analysts have issued ratings for Gilead Sciences, Inc. in the past 12 months.
Is GILD a buy or sell right now?
Based on 18 analyst ratings, GILD has a consensus rating of Buy (2.06/5) with a +22.6% upside to the consensus target of $158.71.
What are the earnings estimates for GILD?
Analysts estimate GILD will report EPS of $8.55 for the period ending 2026-12-31, with revenue estimated at $30.23B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.